| Unique ID issued by UMIN | UMIN000058908 |
|---|---|
| Receipt number | R000067265 |
| Scientific Title | An investigation on the effect of glucosamine intake on gut environments - A double-blind crossover placebo-controlled study - |
| Date of disclosure of the study information | 2025/12/07 |
| Last modified on | 2025/08/27 13:06:20 |
An investigation on the effect of glucosamine intake on gut environments
Effect of glucosamine on gut environments
An investigation on the effect of glucosamine intake on gut environments - A double-blind crossover placebo-controlled study -
Effect of glucosamine on gut environments - A double-blind crossover placebo-controlled study -
| Japan |
Constipation tendency in adults
| Not applicable | Adult |
Others
NO
To examine the effect of glucosamine intake on improving the intestinal environment.
Safety,Efficacy
Gut environment parameters
Blood biochemistry parameters
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
| Food |
Intake of glucosamine 3000mg per day for 14 days
Intake of placebo 3000mg per day for 14 days
| 20 | years-old | <= |
| 59 | years-old | >= |
Male and Female
1) Japanese men and women aged 20 to 59 years at the time of consent.
2) Individuals capable of consistently taking 10 or more supplement tablets per day (can be divided into multiple doses).
3) Individuals with a bowel movement frequency of 3 to 5 times per week.
4) Individuals able to store stool samples collected at home in their refrigerator or freezer for several days until their visit.
1) Individuals with alcohol dependency
2) Individuals taking medications that may influence the study results (e.g., drugs with intestinal regulatory effects, antibiotics, etc.)
3) Individuals routinely consuming health foods that may affect the study results (e.g., supplements containing lactic acid bacteria, oligosaccharides, or those claiming intestinal regulatory effects)
4) Individuals with potential allergy symptoms to test product components (especially shrimp or crab)
5) Individuals participating in other clinical trials
6) Individuals with a history of severe liver, kidney, or heart disease
7) Individuals with a history or current diagnosis of hepatitis
8) Individuals with a history or current diagnosis of diabetes
9) Individuals with a history or current diagnosis of thrombosis
10) Individuals with severe anemia
11) Pregnant women, women who may be pregnant, and breastfeeding women
40
| 1st name | Tomoya |
| Middle name | |
| Last name | Shintani |
TOYO INSTITUTE of FOOD TECHNOLOGY
Research department
666-0026
4-23-2 Minami-Hanayashiki, Kawanishi, Hyogo 666-0026, Japan
072-740-3300
tomoya_shintani@shokuken.or.jp
| 1st name | Tomoya |
| Middle name | |
| Last name | Shintani |
TOYO INSTITUTE of FOOD TECHNOLOGY
Research department
666-0026
4-23-2 Minami-Hanayashiki, Kawanishi, Hyogo 666-0026, Japan
08072169232
tomoya_shintani@shokuken.or.jp
SOUKEN Co., Ltd.
TOYO INSTITUTE of FOOD TECHNOLOGY
Self funding
Japan
Shiba Palace Clinic Institutional Review Board
1-9-10, DaiwaA Hamamatsucho Building 3rd floor, Hamamatsucho, Minato-ku, Tokyo, Japan
03-5408-1555
jimukyoku@mail.souken-r.com
NO
| 2025 | Year | 12 | Month | 07 | Day |
Unpublished
Open public recruiting
| 2025 | Year | 07 | Month | 10 | Day |
| 2025 | Year | 07 | Month | 10 | Day |
| 2025 | Year | 08 | Month | 06 | Day |
| 2025 | Year | 12 | Month | 31 | Day |
| 2025 | Year | 08 | Month | 27 | Day |
| 2025 | Year | 08 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067265